Risankizumab, guselkumab, and ustekinumab were associated with the lowest risk for progression from psoriasis to psoriatic arthritis.

Later onset of vitiligo in patients with melanoma who initiated anti-PD-1 therapy was associated with a lower 3-year mortality rate.

Patients with seborrheic dermatitis are at an increased risk of developing scarring alopecia compared with those without seborrheic dermatitis.

Patients with moderate to severe CSU have greater rates of several immune-mediated comorbidities than patients with mild CSU.

The risk for KC in patients with AD using ruxolitinib cream 1.5% is similar to that of patients using dupilumab or topical corticosteroids.

In adults with psoriasis, IL-23 inhibitors were associated with lower risks for serious infection and all-cause mortality but higher malignancy risk.

Research presented at the 2026 AAD Annual Meeting examined patterns of skin cancer prevalence in adults aged 50 years and ...

Patients with AD initiating ASTs have a high comorbidity rate and disease burden at treatment initiation, with concomitant therapy common at 1 year.

Use of biologics increases the risk for treatment escalation to systemic therapies among patients with inflammatory acne.

Immunosuppressive disease is independently associated with significantly shorter survival among patients with CSCC receiving ICI therapy.

Patients with alopecia areata who did not respond to initial treatment with a JAKi or who did not maintain response may ...

OnabotulinumtoxinA is an effective minimally invasive option for patients with PP, as measured by both clinician- and patient ...